These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 30110717)

  • 1. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
    Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
    Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.
    Farag S; Bacher U; Jeker B; Legros M; Rhyner G; Lüthi JM; Schardt J; Zander T; Daskalakis M; Mansouri B; Manz C; Pabst T
    Bone Marrow Transplant; 2022 Jun; 57(6):990-997. PubMed ID: 35444232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
    Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
    Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
    Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD; Lechowicz MJ; Khoury HJ; Flowers CR; Waller EK
    Clin Cancer Res; 2010 Oct; 16(20):5079-86. PubMed ID: 20739431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final outcomes of escalated melphalan 280 mg/m
    Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
    Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.